Cancer

HRD Testing Best Practices Issued by AMP

AMP has published consensus best practice recommendations to standardize HRD testing in clinical laboratories.

Cancer

Cancer Screenings Continue Years After Guidelines Change to Limit Unnecessary Tests

It can take over a decade for unnecessary cancer screenings to significantly decline after updated guidelines advise against them.

Cancer

Labcorp Expands Oncology Portfolio

Labcorp has expanded its precision oncology portfolio with new tests for solid tumors and blood cancers to support diagnostic development.

Study IDs Two New Breast Cancer Genes in Black Women

May 15, 2025 | Breast

A groundbreaking genetic study identified two novel breast cancer-linked genetic variants in Black South African women.

Oncologists: More Advanced Cancers, Current Tests Not Catching Cancer Recurrence Early Enough

May 13, 2025 | Cancer

Oncologists are seeing more advanced cancer cases due to screening barriers and are concerned current tests aren’t effective enough.

At-Home Self-Collection Device for Cervical Cancer Screening Gets FDA Approval

May 12, 2025 | Cervical (HPV)

Teal Health has received FDA approval for the Teal Wand, a prescription-based self-collection device for cervical cancer screening.

Algorithms Can Help Predict Undiagnosed Cancer

May 7, 2025 | Cancer

New predictive algorithms using routine health data and blood tests significantly improve early detection of 15 cancers.

Ibex Breast Demonstrates High Accuracy, Efficiency in Study

May 6, 2025 | Breast

A new peer-reviewed study confirms that Ibex Breast significantly enhances accuracy, speed, and efficiency of breast pathology evaluations.

Breakthrough Device Designation Granted for Roche’s VENTANA TROP2 RxDx Device

May 5, 2025 | Lung Cancer

Roche’s VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.

Prostate Cancer Biomarkers and PVSA Research Presented

Apr 30, 2025 | Prostate

Fellow Health showcased innovative research, emphasizing mail-in semen testing to enhance prostate cancer diagnostics and PVSA care.

EvoLiver Test Receives FDA Breakthrough Device Designation

Apr 30, 2025 | Unknown Origin & Other Cancer Types

Mursla Bio has received FDA Breakthrough Device Designation for EvoLiver, a novel blood test using Dynamic Biopsy technology.

Veracyte Expands Availability of Decipher Prostate Test

Apr 25, 2025 | Prostate

Veracyte has launched Decipher Prostate test, a Medicare-covered test for guiding treatment in metastatic prostate cancer.

Landmark Longitudinal Prostate Cancer Study Released

Apr 23, 2025 | Prostate

A new study confirms Cleveland Diagnostics’ IsoPSA test effectively differentiates between low- and high-risk prostate cancer patients.

ctMoniTR Project Gets new Research Findings from Biodesix and Bio-Rad

Apr 23, 2025 | Cancer

Biodesix and Bio-Rad contributed findings to ctMoniTR showing that changes in ctDNA are strongly associated with treatment outcomes.

Labcorp Plasma Detect and PGDx Elio Plasma Focus Dx Launched

Apr 23, 2025 | Cancer

Labcorp has expanded its precision oncology portfolio with two diagnostic tools—Labcorp Plasma Detect and PGDx elio plasma focus Dx.

Liquid Biopsy Is an Early Cancer Screening Breakthrough Technology

Apr 22, 2025 | Cancer

Liquid biopsy is a groundbreaking, non-invasive method for early cancer detection and monitoring, offering significant clinical potential.

Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in SEER Specialized Database Release

Apr 21, 2025 | Prostate

Decipher Prostate Genomic Classifier data is included in a new SEER Program database, enabling the study of prostate cancer outcomes.

CAP Updates Cancer Protocols to Improve Diagnostic Accuracy

Apr 21, 2025 | Cancer

CAP has released new protocols for endocrine tumors and updated breast cancer guidelines to improve diagnostic precision.

Category: Cancer

Cancer

Cancer

Cancer